The impact of molecular biology on drug discovery

2006 ◽  
Vol 34 (2) ◽  
pp. 313-316 ◽  
Author(s):  
G.P. Belfield ◽  
S.J. Delaney
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Clinical Efficacy ◽  
Drug Targets ◽  
Safety Data ◽  
Vital Role ◽  
Drug Discovery And Development ◽  
New Drug ◽  
Whole Process ◽  
The Impact

The discipline of molecular biology has become increasingly important in recent times for the process of drug discovery. We describe the impact of molecular biology across the whole process of drug discovery and development, including (i) the identification and validation of new drug targets, (ii) the development of molecular screens to find new candidate drugs, and (iii) the generation of safety data and competences leading to enhanced clinical efficacy. We also speculate on emerging developments in drug discovery where it seems likely that molecular biology will play an even more vital role in the generation of future therapies.

Drug discovery in tuberculosis. New drug targets and antimycobacterial agents

2018 ◽  
Vol 150 ◽  
pp. 525-545 ◽  
Author(s):  
André Campaniço ◽  
Rui Moreira ◽  
Francisca Lopes
Keyword(s):  
Drug Discovery ◽  
Drug Targets ◽  
New Drug ◽  
Antimycobacterial Agents

Epigenetics—an emerging and highly promising source of new drug targets

MedChemComm ◽  
2012 ◽  
Vol 3 (2) ◽  
pp. 162-166 ◽  
Author(s):  
Nessa Carey
Keyword(s):  
Gene Expression ◽  
Drug Discovery ◽  
Drug Targets ◽  
Epigenetic Modifications ◽  
Regulatory Process ◽  
Human Diseases ◽  
Histone Proteins ◽  
New Drug ◽  
Promising Source

Epigenetic modifications to DNA and its associated histone proteins are major influences on gene expression. This regulatory process is disrupted in cancer and a range of chronic human diseases, and provides attractive new intervention points and targets for drug discovery.

scholarly journals The Stages of Drug Discovery and Development Process

2019 ◽  
Vol 7 (6) ◽  
pp. 62-67 ◽  
Author(s):  
Amol B Deore ◽  
Jayprabha R Dhumane ◽  
Rushikesh Wagh ◽  
Rushikesh Sonawane
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Drug Development ◽  
Development Process ◽  
Regulatory Requirements ◽  
Drug Discovery And Development ◽  
Biological Targets ◽  
New Drug ◽  
Initial Discovery ◽  
New Research

Drug discovery is a process which aims at identifying a compound therapeutically useful in curing and treating disease. This process involves the identification of candidates, synthesis, characterization, validation, optimization, screening and assays for therapeutic efficacy. Once a compound has shown its significance in these investigations, it will initiate the process of drug development earlier to clinical trials. New drug development process must continue through several stages in order to make a medicine that is safe, effective, and has approved all regulatory requirements. One overall theme of our article is that the process is sufficiently long, complex, and expensive so that many biological targets must be considered for every new medicine ultimately approved for clinical use and new research tools may be needed to investigate each new target.  From initial discovery to a marketable medicine is a long, challenging task. It takes about 12 - 15 years from discovery to the approved medicine and requires an investment of about US $1 billion. On an average, a million molecules screened but only a single is explored in late stage clinical trials and is finally made obtainable for patients. This article provides a brief outline of the processes of new drug discovery and development.   

scholarly journals Conference 2015: Drug Discovery and Development in the Post Genomic Era. An international symposium held jointly by CSPS and CC-CRS, May 26-28, 2015, Toronto, ON, Canada

2015 ◽  
Vol 18 (3) ◽  
pp. 1
Author(s):  
Beverley Berekoff
Keyword(s):  
Drug Discovery ◽  
Drug Targets ◽  
New Technologies ◽  
Pharmaceutical Sciences ◽  
Drug Discovery And Development ◽  
University Of Toronto ◽  
Genome Wide ◽  
Lifetime Achievement ◽  
New Methodologies ◽  
University Of Manitoba

Plenaries and Special Presentations:Shana Kelley, University of Toronto:  "New Technologies for Ultrasensitive Analysis of Clinically-relevant Biomolecules"Richard Hargreaves, BIOGEN IDEC:  "Imaging in CNS Drug Discovery and Development"Roger Williams:  CSPS Lifetime Achievement Award - "0.5 X 102:  Looking Back and Forward"Neal Davies, University of Manitoba:  CSPS Award of Leadership in Canadian Pharmaceutical Sciences - "30 Years of Coffee, Beer and Serendipity in Pharmacy Research"Conference Sessions:Special CSPS Session: The Future of Pharmaceutical Sciences1. The Evolving Business of Pharmaceuticals2. Analysis of Peptide and Protein Drug Targets by LC/MS/MS3. Mucosal Drug Delivery4. New Methodologies of Genome Wide Target Validation5. Regulatory Updates and Developments6. Antibody-based Therapeutics7. Imaging in Drug Delivery8. Nuclear Receptors in Drug Discovery9. IV-IVC Modeling and Simulation as a Tool to Facilitate Drug Development and Marketing10. Pharmacogenomics in Drug Development11. Bioavailability of Novel Dosage Forms

scholarly journals Academic Discovery of Anticancer Drugs: Historic and Future Perspectives

2019 ◽  
Vol 3 (1) ◽  
pp. 385-408 ◽  
Author(s):  
Alessandro Carugo ◽  
Giulio F. Draetta
Keyword(s):  
Drug Discovery ◽  
Anticancer Drug ◽  
Cancer Biology ◽  
Drug Targets ◽  
Nonprofit Sector ◽  
Critical Issue ◽  
Drug Discovery And Development ◽  
New Horizons ◽  
Innovation Research ◽  
History Of

The identification and prosecution of meritorious anticancer drug targets and the discovery of clinical candidates represent an extraordinarily time- and resource-intensive process, and the current failure rate of late-stage drugs is a critical issue that must be addressed. Relationships between academia and industry in drug discovery and development have continued to change over time as a result of technical and financial challenges and, most importantly, to the objective of translating impactful scientific discoveries into clinical opportunities. This Golden Age of anticancer drug discovery features an increased appreciation for the high-risk, high-innovation research conducted in the nonprofit sector, with the goals of infusing commercial drug development with intellectual capital and curating portfolios that are financially tenable and clinically meaningful. In this review, we discuss the history of academic-industry interactions in the context of antidrug discovery and offer a view of where these interactions are likely headed as we continue to reach new horizons in our understanding of the immense complexities of cancer biology.

Sign in / Sign up

Export Citation Format

Share Document